Ra Pharmaceuticals Inc (RARX) Return on Equity ROE from the fourth quarter 2019 to fourth quarter 2018 and annually, average high and low, overall ranking from Dec 31 2019 to Dec 31 2018 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Ra Pharmaceuticals Inc   (RARX)

Ra Pharmaceuticals Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Ra Pharmaceuticals Inc in the fourth quarter 2019?
Ra Pharmaceuticals Inc recorded a cumulative net loss of $-103 million during 12 months ending in the fourth quarter 2019, resulting in a negative return on equity (ROE) of -44.61%.

Within the Major Pharmaceutical Preparations industry 144 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2019 from 0 to 3762.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Dec 31 2019)
IV. Quarter		 (Sep 30 2019)
III. Quarter		 (Jun 30 2019)
II. Quarter		 (Mar 31 2019)
I. Quarter		 (Dec 31 2018)
IV. Quarter
Y / Y Equity Change 26.55 % 265.1 % 82.98 % 75.99 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -103 -82 -74 -67 -65
Return On Equity (TTM) -44.61 % -37.93 % -45.14 % -47.05 % -52.89 %
RARX's Total Ranking # 3762 # 0 # 0 # 0 # 0
Equity (TTM) in Millions 262 294 174 191 207
Seq. Equity Change -10.77 % 69.13 % -9.18 % -7.66 % 157.42 %
Seq. Net Income Change - - - - -

Back to RARX Management Effectiveness >> RARX's 5 Years Annual ROE >> Compare RARX ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 145
Sector # 369
Overall # 3762

Return On Equity Statistics
High Average Low
-17.96 %
-36.77 %
-52.89 %
(Mar 31 2018)   (Dec 31 2018)





RARX Annual Return On Equity (Dec 31 2019)
2019		 (Dec 31 2018)
2018		 (Dec 31 2017)
2017		 (Dec 31 2014)
2016
Total Equity in Millions 262 207 69 -37 0
Y / Y Equity Change 26.55 % 199.37 % - - -
Net Income in Millions -103 -65 -54 -5 0
Y / Y Net Income Change - - - - -
Return On Equity -39.18 % -31.36 % -78.69 % - -

Back to RARX Management Effectiveness >> RARX's 5 Years Annual ROE >> Compare RARX ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
RARX's' Return on Equity at Yahoo Finance
RARX's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for RARX's Competitors
Subscribers only: Roe for Ra Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Equity for RARX's Customers




Companies with similar Return On Equity at Dec 31 2019, within Healthcare Sector ROE

Date modified: 2026-09-18T13:11:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.